Thoughts on ‘Efficacy of RestoreX after prostatectomy: open-label phase of an RCT’

IF 1.6 Q3 UROLOGY & NEPHROLOGY BJUI compass Pub Date : 2024-02-22 DOI:10.1002/bco2.320
Mustafa Ganijee, Rasi Mizori, Awab Ahmad, Mirza Hashim Ahmad, Malik Takreem Ahmad
{"title":"Thoughts on ‘Efficacy of RestoreX after prostatectomy: open-label phase of an RCT’","authors":"Mustafa Ganijee,&nbsp;Rasi Mizori,&nbsp;Awab Ahmad,&nbsp;Mirza Hashim Ahmad,&nbsp;Malik Takreem Ahmad","doi":"10.1002/bco2.320","DOIUrl":null,"url":null,"abstract":"<p>We congratulate Zganjar et al. on their evaluation of the effects of RestoreX penile traction therapy following post-prostatectomy.<span><sup>1</sup></span> This single-centre, randomised trial offers valuable insights into the impact of RestoreX on a common yet under-researched complication: reduced penile length. Given that prostate cancer is the most common cancer worldwide,<span><sup>2</sup></span> and prostatectomy remains the definitive treatment of choice, this study addresses some important concerns related to post-prostatectomy complications and potential management strategies.</p><p>However, several factors might constrain the generalisability of these findings. Firstly, the study's narrow demographic scope and its single-centre design mean that lack of patient diversity is a limitation. With the inclusion of 82 men, only 45 of whom there is 9-month data available for, extrapolating these results to the broader population is challenging. A single-centre study inherently reflects the patients within that specific centre and does not fully reflect the diverse demographics of patients affected by this complication globally. Post-prostatectomy complications are a pervasive issue, affecting a myriad of patient demographics worldwide,<span><sup>3</sup></span> and so this underscores the importance of research encompassing a broader range of demographics.</p><p>We also noted the significant dropout rate given the study's limited participant pool. With 45 participants out of an initial 82, this indicates a dropout rate of more than 45% of participants, further restricting the data's generalisability. Such significant dropout rates can introduce biases, and it is therefore essential to understand the reasons for these dropouts, as these may reveal potential challenges associated with RestoreX. The small sample size inherently diminishes the study's power, and this impacts the interpretation and subsequent conclusions.<span><sup>4</sup></span></p><p>Furthermore, the study monitors outcomes up to 9 months for the 45 men who completed the whole study. Although these findings are promising, the ramifications of a prostatectomy and the trajectory of post-operative recovery can span years.<span><sup>5</sup></span> A longer follow-up would offer deeper insights into RestoreX's long-term effects and reveal any latent side effects that might not manifest during shorter usage periods. Such comprehensive data would allow both patients and healthcare providers to have a holistic understanding of the medications, encompassing their prolonged effects and potential side effects.</p><p>To conclude, while Zganjar et al. study sheds light on the benefits of RestoreX treatment on penile length decrease, further studies should focus on including patients from a broader demographic to represent the diverse populations best that this complication affects. We urge further exploration into the reasons behind more than 45% of participants in the study dropping out and how this cause can be managed to increase adherence, particularly in the real world. Finally, we hope that future studies will explore the effects of RestoreX for longer periods of time, thereby offering insight into its long-term effects and any associated complications/side effects that patients and healthcare practitioners should be aware of.</p><p>Sincerely,</p><p>Dr Mustafa Ganijee</p><p>General Practitioner</p><p>Ashton GP Service, 193 Old Street, Aston-under-Lyne, OL6 7SR</p><p>I, Dr Mustafa Ganijee, the first author, wish to declare that I am a general practitioner with a specialist interest in male sexual health, especially with regard to the private treatment of erectile dysfunction and premature ejaculation. Thus, the opinions and critical commentary contained within this letter are informed by my clinical experience. This personal interest does not, however, influence the integrity or objectivity of my professional perspective. The points presented below are presented on the basis of scientific evidence and unbiased professional judgement. There are also no conflicts of interest or financial interests that have directly or indirectly influenced this letter to the editor.</p>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 4","pages":"515-516"},"PeriodicalIF":1.6000,"publicationDate":"2024-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.320","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJUI compass","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bco2.320","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

We congratulate Zganjar et al. on their evaluation of the effects of RestoreX penile traction therapy following post-prostatectomy.1 This single-centre, randomised trial offers valuable insights into the impact of RestoreX on a common yet under-researched complication: reduced penile length. Given that prostate cancer is the most common cancer worldwide,2 and prostatectomy remains the definitive treatment of choice, this study addresses some important concerns related to post-prostatectomy complications and potential management strategies.

However, several factors might constrain the generalisability of these findings. Firstly, the study's narrow demographic scope and its single-centre design mean that lack of patient diversity is a limitation. With the inclusion of 82 men, only 45 of whom there is 9-month data available for, extrapolating these results to the broader population is challenging. A single-centre study inherently reflects the patients within that specific centre and does not fully reflect the diverse demographics of patients affected by this complication globally. Post-prostatectomy complications are a pervasive issue, affecting a myriad of patient demographics worldwide,3 and so this underscores the importance of research encompassing a broader range of demographics.

We also noted the significant dropout rate given the study's limited participant pool. With 45 participants out of an initial 82, this indicates a dropout rate of more than 45% of participants, further restricting the data's generalisability. Such significant dropout rates can introduce biases, and it is therefore essential to understand the reasons for these dropouts, as these may reveal potential challenges associated with RestoreX. The small sample size inherently diminishes the study's power, and this impacts the interpretation and subsequent conclusions.4

Furthermore, the study monitors outcomes up to 9 months for the 45 men who completed the whole study. Although these findings are promising, the ramifications of a prostatectomy and the trajectory of post-operative recovery can span years.5 A longer follow-up would offer deeper insights into RestoreX's long-term effects and reveal any latent side effects that might not manifest during shorter usage periods. Such comprehensive data would allow both patients and healthcare providers to have a holistic understanding of the medications, encompassing their prolonged effects and potential side effects.

To conclude, while Zganjar et al. study sheds light on the benefits of RestoreX treatment on penile length decrease, further studies should focus on including patients from a broader demographic to represent the diverse populations best that this complication affects. We urge further exploration into the reasons behind more than 45% of participants in the study dropping out and how this cause can be managed to increase adherence, particularly in the real world. Finally, we hope that future studies will explore the effects of RestoreX for longer periods of time, thereby offering insight into its long-term effects and any associated complications/side effects that patients and healthcare practitioners should be aware of.

Sincerely,

Dr Mustafa Ganijee

General Practitioner

Ashton GP Service, 193 Old Street, Aston-under-Lyne, OL6 7SR

I, Dr Mustafa Ganijee, the first author, wish to declare that I am a general practitioner with a specialist interest in male sexual health, especially with regard to the private treatment of erectile dysfunction and premature ejaculation. Thus, the opinions and critical commentary contained within this letter are informed by my clinical experience. This personal interest does not, however, influence the integrity or objectivity of my professional perspective. The points presented below are presented on the basis of scientific evidence and unbiased professional judgement. There are also no conflicts of interest or financial interests that have directly or indirectly influenced this letter to the editor.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于 "前列腺切除术后 RestoreX 的疗效:RCT 的开放标签阶段 "的想法
我们祝贺Zganjar等人对前列腺切除术后RestoreX阴茎牵引疗法的效果进行了评估1。这项单中心随机试验就RestoreX对一种常见但研究不足的并发症--阴茎长度缩短--的影响提供了有价值的见解。鉴于前列腺癌是全球最常见的癌症2 ,而前列腺切除术仍是最终的治疗选择,本研究探讨了与前列腺切除术后并发症相关的一些重要问题以及潜在的管理策略。首先,这项研究的人口统计范围较窄,而且是单中心设计,这意味着患者缺乏多样性是一个限制因素。研究共纳入了 82 名男性患者,其中只有 45 名患者有 9 个月的数据,因此将这些结果推广到更广泛的人群中具有挑战性。单个中心的研究本质上反映的是该中心的患者情况,并不能完全反映全球受这种并发症影响的患者的人口统计学特征。前列腺切除术后并发症是一个普遍存在的问题,影响着全球众多患者的人口结构3,因此这凸显了研究涵盖更广泛人口结构的重要性。在最初的 82 名参与者中,有 45 人退出了研究,这表明退出率超过了 45%,进一步限制了数据的普遍性。如此高的辍学率可能会造成偏差,因此了解辍学原因至关重要,因为这可能会揭示与 RestoreX 相关的潜在挑战。4 此外,该研究对完成整个研究的 45 名男性进行了长达 9 个月的结果监测。尽管这些研究结果令人鼓舞,但前列腺切除术的影响和术后恢复的轨迹可能长达数年。5 更长时间的随访将有助于深入了解 RestoreX 的长期效果,并揭示在较短使用期内可能无法显现的任何潜在副作用。总之,虽然 Zganjar 等人的研究揭示了 RestoreX 治疗对阴茎长度减少的益处,但进一步的研究应侧重于纳入更广泛人群中的患者,以最好地代表这一并发症所影响的不同人群。我们敦促进一步探讨超过 45% 的参与者退出研究的原因,以及如何处理这一原因以提高依从性,尤其是在现实世界中。最后,我们希望未来的研究能对 RestoreX 的效果进行更长时间的探索,从而深入了解其长期效果以及任何相关并发症/副作用,让患者和医疗从业人员有所了解。第一作者 Mustafa Ganijee 博士谨此声明,我是一名全科医生,专攻男性性健康,尤其是勃起功能障碍和早泄的私人治疗。因此,本信中的观点和批判性评论是根据我的临床经验撰写的。不过,这种个人兴趣并不会影响我专业观点的完整性或客观性。以下观点是基于科学证据和公正的专业判断提出的。此外,也没有任何利益冲突或经济利益直接或间接影响到这封致编辑的信。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
0
审稿时长
12 weeks
期刊最新文献
Issue Information Issue Information Reliability of mpMRI in diagnosing cancer prostate following intravesical BCG for bladder cancer Understanding the long-term impact of the COVID-19 pandemic on non-muscle-invasive bladder cancer outcomes: 12-Month follow-up data from the international, prospective COVIDSurg Cancer study Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1